Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Classic Galactosemia, Sorbitol ...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that ...
The panel discussion will be accessible via webcast through a link on the Investor Events and Presentations section of the Coherus website: Coherus Contact Information: For Investors: Jodi Sievers VP ...
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
LONDON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- StoneX Group Inc. (NASDAQ: SNEX); today announced that its wholly owned subsidiary, StoneX Financial Limited (“StoneX Financial”), has been awarded General ...
BOCA RATON, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- FlexShopper, Inc. (Nasdaq: FPAY) (the “Corporation”) announced today the tentative calendar for its previously proposed rights offering (“Rights ...
The Vietnam Fintech Summit International Conference provides an ideal opportunity for Fintech startups to gain a deeper ...
"The Global State of Tobacco Harm Reduction 2024: A Situation Report" says safer nicotine products, such as nicotine vapes, ...
For assistance finding and collaborating with Taiwan's leading innovators, please visit: Or email: [email protected ...
SBM Offshore reports the transaction details related to its EUR130 million (c. US$140 million) share repurchase program for the period November 21, 2024 through November 27, 2024.
Bang & Olufsen launches private placement of new shares targeting proceeds of around DKK 228 million ...
On November 26, 2024, all material closing conditions were satisfied, and ILUS delivered the necessary documentation to its transfer agent to finalize the share transfer to Fusion Fuel. Concurrently, ...